©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Involvement of a Mitogen-activated Protein Kinase Signaling Pathway in the Regulation of Urokinase Promoter Activity by c-Ha-ras(*)

(Received for publication, April 21, 1995; and in revised form, July 31, 1995)

Ernst Lengyel Evan Stepp Rebecca Gum Douglas Boyd (§)

From the Department of Tumor Biology/Head and Neck Surgery, M.D. Anderson Cancer Center, Houston, Texas 77030

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

The expression of the urokinase-type plasminogen activator, which plays a crucial role in tissue remodeling by controlling the synthesis of the broadly acting plasmin serine protease, is regulated by several tyrosine kinases. Since the actions of these tyrosine kinases is dependent on the activation of ras proteins, we undertook a study to identify signaling events downstream of ras responsible for the stimulation of urokinase promoter activity. Transient expression of an activated c-Ha-ras in OVCAR-3 cells, which do not harbor the mutated oncogene, led to a dose-dependent trans-activation of the urokinase promoter. A sequence residing between -2109 and -1964 was critical for the stimulation of the urokinase promoter by c-Ha-ras. Mutation of an AP-1 and a PEA3 site at -1967 and -1973, respectively, or the co-expression of a transactivation domain-lacking c-jun substantially impaired the ability of c-Ha-ras to stimulate urokinase promoter activity. The induction of the urokinase promoter by ras was completely blocked by expression of a dominant negative c-raf expression vector and substantially reduced in cells made to co-express a catalytically inactive mitogen-activated protein kinase kinase. Further, the expression of an ERK1/ERK2-inactivating phosphatase (CL100) abrogated the stimulation of the urokinase promoter by c-Ha-ras. These data argue for a role of a mitogen-activated protein kinase-dependent signaling pathway in the regulation of urokinase promoter activity by ras.


INTRODUCTION

The urokinase-type plasminogen activator has been implicated in a variety of physiological and pathological processes including prostatic involution, cytotrophoblast implantation, and tumor cell invasion, all of which require extensive extracellular matrix proteolysis(1, 2, 3) . Urokinase facilitates this process by mediating the conversion of the abundant zymogen, plasminogen, into the widely acting serine protease plasmin, the latter which degrades several extracellular matrix components including laminin, fibronectin, and possibly type IV collagen(4, 5) . Transcription of the urokinase gene gives rise to a 2.5-kilobase mRNA(6) , which is subsequently translated into a single chain 50-kDa proenzyme (7, 8) and secreted into the extracellular space. The steady state level of urokinase mRNA is determined at two levels. Firstly, the expression of the gene is regulated by 2.1 kilobases of the 5`-flanking sequence(9) . Secondly, recent studies have indicated that 3`-untranslated sequences play a role in determining the stability of the urokinase mRNA(10) .

Several studies have indicated that urokinase expression is regulated by growth factors (HGF/SF, EGF), (^1)which bind to transmembrane receptor protein tyrosine kinases, and by non-receptor protein tyrosine kinases including v-src and v-yes(11, 12, 13) . One of the early events in this pathway involves the coupling of the ligand-activated receptor protein tyrosine kinase to ras through Grb2.sos or Shc Grb2.sos, this increasing the exchange of GTP for GDP and culminating in an activated ras(14, 15) . The pivotal role of ras in mediating the signal generated by tyrosine kinases has been deduced from several experimental observations. First and foremost, inhibitory ras mutant proteins (16) block the stimulation of growth and transformation of NIH 3T3 cells by oncogenic tyrosine kinases. Secondly, revertant clones isolated from activated ras-transformed NIH 3T3 cells are resistant to retransformation by protein tyrosine kinase-encoding oncogenes(17) . Thirdly, ras, like protein tyrosine kinases, elevates urokinase mRNA levels in chick embryo fibroblasts(13) .

However, the events connecting the ras signal to altered gene expression are still not entirely clear. Certainly, the involvement of c-raf, mitogen-activated protein kinase kinase (MAPKK also referred to as MEK) and mitogen-activated protein kinases (MAPK), which form successive tiers in a ras-dependent signal transduction pathway, has been suggested from several reports. c-raf is a protein serine/threonine kinase which acts as a cytoplasmic signal transducer downstream of ras(18) and is an immediate upstream activator of MAPKK (MEK1)(19, 20) . MEK1, in turn, activates the extracellular signal-regulated kinase (ERK) group of MAPK (21) which regulates AP-1 activity via increased transcription of the c-fos gene (22) as a consequence of p62/elk phosphorylation. Alternatively, modulation of gene expression by ras can also be achieved in a c-raf-independent pathway involving the c-jun amino-terminal kinase (JNK)(23, 24) .

Although ras increases the steady state level of urokinase mRNA(13) , the mechanism by which this is accomplished has not been elucidated. We therefore undertook a study to determine the role of a MAPK pathway in the regulation of urokinase expression by c-Ha-ras. We report, herein, that the stimulation of urokinase promoter activity by ras, is dependent on one, or multiple, MAPKs and is mediated via the stimulation of an AP-1 and PEA3 sequence located at -1967 and -1973, respectively, as well as a region residing between -1956 and -1905 in the urokinase promoter.


EXPERIMENTAL PROCEDURES

Vectors

The 6.6-kilobase BamHI fragment from the activated c-Ha-ras oncogene from the T24 bladder carcinoma cells cloned in a pSV2neo plasmid (25) was used for ras transfections. The TAM 67 vector, encoding a c-jun protein lacking the transactivation domain (amino acids 3-122 absent) of the molecule, has been described elsewhere(26, 27) . The CL100 expression vector (CL100 SG5), kindly provided by S. M. Keyse, University of Dundee, United Kingdom, contains the CL100 cDNA (encoding residues 1-314) of the CL100 protein (28) fused at the carboxyl terminus to sequences encoding a single copy of the myc epitope tag EQKLISEEDL and ligated into a pSG5 vector (Stratagene). The K97M mutant expression vector encodes a catalytically inactive MEK1 in which a methionine is substituted for a lysine in the ATP binding site(29, 30) . The c-raf C4 expression vector encodes c-raf lacking the conserved regions 2 and 3 and therefore lacks the kinase domain contained in the latter(18) . The 3 times AP-1 pBLCAT construct consists of 3 AP-1 tandem repeats upstream of a thymidine kinase minimal promoter-CAT reporter (pBLCAT)(31) . The mutated urokinase promoter CAT reporter constructs have been described elsewhere(32) .

Cell Lines

The OVCAR-3 cell line was derived from a malignant ascites of a patient with progressive adenocarcinoma of the ovary(33) . Codons 12, 13, and 61 of c-Ha-ras are not mutated in the OVCAR-3 cells. (^2)All cells were maintained in McCoy's medium 5A supplemented with 10% fetal bovine serum. For the collection of conditioned medium, cells were plated in the presence of serum-containing medium and 24 h later changed to serum-free medium (McCoy's medium 5A supplemented with 4 µg/ml transferrin, 5 µg/ml of insulin, and 10 ng/ml EGF). Conditioned medium was collected 24 h later, and cells were counted.

Measurement of Secreted Urokinase by Western Blotting

The amount of urokinase in the conditioned medium was determined by Western blotting. Briefly, conditioned medium from equal numbers of cells was denatured in the absence of reducing agent and electrophoresed in a 12.5% SDS-polyacrylamide gel electrophoresis gel. The resolved proteins were transferred to a nitrocellulose filter. The filter was blocked with 3% bovine serum albumin and incubated sequentially with a rabbit polyclonal antibody to human urokinase (product 389, American Diagnostica, Greenwich, CT). Reactive proteins were visualized by ECL as described by the manufacturer (Amersham).

Chloramphenicol Acetyltransferase (CAT) Assays

OVCAR-3 cells were transfected by a calcium phosphate method with CAT reporter constructs fused to the wild type (2109 bp), mutated, or 5`-deleted fragments of the human urokinase promoter (9, 32) without, or with, the c-Ha-ras expression vector. All transient transfections were performed in the presence of 5 µg of a beta-galactosidase expression vector to correct for differences in transfection efficiencies. Briefly, DNA precipitate formed in the presence of 124 mM calcium chloride in a buffer containing 15 mM Hepes (pH 7.1), 280 mM NaCl, 1.5 mM Na(2)HPO(4) was added to 50% confluent OVCAR-3 cells. After 6 h, the cells were changed to fresh 10% fetal bovine serum-containing medium and cultured for an additional 36 h. The cells were harvested and lysed by repeated freeze-thaw cycles in a buffer containing 0.25 M Tris-Cl (pH 7.8). Transfection efficiencies were determined by assaying for beta-galactosidase activity. CAT activity was measured by incubating cell lysate (normalized for transfection efficiency) at 37 °C for 6-8 h with 4 µM [^14C]chloramphenicol and 1 mg/ml acetyl coenzyme A. After 3 h, the acetyl coenzyme A was replenished. The mixture was extracted with ethyl acetate, and acetylated products were subjected to thin layer chromatography using chloroform:methanol (95:5) as a mobile phase. The amount of acetylated [^14C]chloramphenicol was determined using a 603 Betascope.


RESULTS

Expression of c-Ha-ras Increases Urokinase Promoter Activity

The OVCAR-3 cell line, which does not contain an activated ras, secretes an undetectable level of urokinase, as determined by Western blotting (Fig. 1). We therefore elected to use the OVCAR-3 cells to study the inductive effect of ras on urokinase promoter activity. Transient expression of c-Ha-ras in OVCAR-3 cells led to a dose-dependent increase in urokinase promoter activity (Fig. 2). Addition of 4 µg of c-Ha-ras caused a 10-fold stimulation of urokinase promoter activity whereas 50 ng of the oncogene increased CAT activity three times. The induction of the urokinase promoter by ras could not be accounted for by a vector effect since 4 µg of the pSV2neo expression vector did not elevate CAT activity over that achieved without the oncogene.


Figure 1: OVCAR-3 cells are low expressors of urokinase. Conditioned medium collected from OVCAR-3 cells and from the high urokinase-producing OC-7 cells (Positive Control) was harvested, clarified by centrifugation, and the cells were enumerated. Conditioned medium, normalized to cell number, and authentic, recombinant, urokinase (rSC-uPA) was denatured, in the absence of reducing agent, and electrophoresed in a 12.5% acrylamide gel. The resolved proteins were transferred to a nitrocellulose filter. The filter was blocked with a solution containing 3% bovine serum albumin and incubated with a polyclonal antibody to human urokinase. Reactive proteins were visualized by ECL.




Figure 2: Transient expression of c-Ha-ras increases urokinase promoter activity in a dose-dependent manner. OVCAR-3 cells were transiently transfected at 50% confluency with 10 µg of a CAT reporter driven by the wild type (2109 bp) urokinase promoter in the absence, or in the presence, of varying amounts of a vector bearing the c-Ha-ras sequence or 4 µg of the vector alone (pSV2neo). All transfections were performed in the presence of 5 µg of a beta-galactosidase-expressing vector. After 5 h, the medium was changed and cells were cultured for an additional 36 h. The cells were harvested and assayed for beta-galactosidase activity. Cell extracts, corrected for differences in transfection efficiency, were incubated with [^14C]chloramphenicol for 8 h. The mixture was extracted with ethyl acetate and subjected to thin layer chromatography. The conversion of [^14C]chloramphenicol to acetylated derivatives was determined with a 603 Betascope.



Stimulation of Urokinase Promoter Activity by ras Requires a Region of the Promoter Residing between -2109 and -1964

To determine the region of the urokinase promoter required for its stimulation by ras, we co-transfected OVCAR-3 cells with a CAT reporter driven by 5` deletion fragments of the urokinase promoter and the ras expression vector (Fig. 3). A dramatic stimulation of the urokinase promoter was evident with 2109 bp of the 5`-flanking sequence. This stimulation was almost entirely abolished when the CAT reporter was fused to 1964 or to 1870 bp of the 5`-flanking sequence. These data suggest that a sequence residing between -2109 and -1964 is critical for the stimulation by the ras oncogene.


Figure 3: Activation of the urokinase promoter by c-Ha-ras requires a sequence residing between -2109 and -1964 in the 5`-flanking sequence of the urokinase gene. OVCAR-3 cells were transiently co-transfected, as described in the legend to Fig. 2, with 4 µg of the c-Ha-ras expression vector or an equimolar amount of the pSV2neo vector, 10 µg of a CAT reporter driven by the indicated 5`-deleted fragment of the urokinase promoter, and 5 µg of a vector encoding the beta-galactosidase gene. After 48 h, the cells were harvested and transfection efficiencies were determined by beta-galactosidase activity. Cell extract, normalized for transfection efficiency, was incubated with [^14C]chloramphenicol for 8 h, and acetylated products were extracted with ethyl acetate and subjected to thin layer chromatography. The conversion of [^14C]chloramphenicol to acetylated derivatives was determined with a 603 Betascope.



Stimulation of the Urokinase Promoter by ras Requires Binding Sites for PEA3 and AP-1

The region of the urokinase promoter residing between -2109 and -1964 contains binding sites for AP-1 and PEA3 shown to be required for the stimulation of several inducible genes (34, 35) . Mutation of the AP-1 binding site at -1967 (mutant B) resulted in a dramatic reduction in the ability of ras to stimulate the urokinase promoter (Fig. 4). Likewise, mutation of a PEA3 (mutant A) motif at -1973 also impaired the ability of ras to stimulate the urokinase promoter, and this may be related to the observations that c-ets family members play a key role in the regulation of gene expression by ras(36, 37) . Mutation of two regions of the urokinase promoter (mutant I and F) shown to be required for the maximal stimulation by phorbol ester (32) reduced the stimulation by ras between 40 and 60%. In contrast, an AP-1 sequence residing at -1885 did not appear to be critical for the stimulation by ras since [^14C]chloramphenicol conversion was unchanged when this site was mutated (mutant G).


Figure 4: The stimulation of urokinase promoter activity by c-Ha-ras requires AP-1 and PEA3 binding sites in the 5`-flanking sequence of the urokinase gene. OVCAR-3 cells were transiently co-transfected, as described in the legend to Fig. 2, with 8 µg of a CAT reporter driven by the wild type (WT) or the point-mutated (A, B, I, F, G) urokinase promoter with (+) or without(-) 4 µg of c-Ha-ras expression vector or the empty expression vector alone (pSV2neo). CAT activity is indicated numerically as the percent of [^14C]chloramphenicol converted. The schematic to the right shows a representation of the mutated region (solid boxes) of the urokinase promoter. The numbers above the arrows refer to the position relative to the urokinase transcription start site. Mutated urokinase promoter constructs are described in more detail elsewhere(32) .



Stimulation of Urokinase Promoter Activity by ras Is Countered by the Expression of a Transactivation Domain-lacking c-jun

The observation that mutation of an AP-1 binding site could diminish the stimulation of the urokinase promoter activity by ras suggested the involvement of transcription factors which bind to this site. To further address this possibility, we transiently transfected OVCAR-3 cells with the urokinase promoter-driven CAT reporter and ras with, or without, an expression vector bearing a c-jun mutant (TAM 67). This c-jun mutant lacks amino acids 3-122 and is unable to transactivate AP-1-containing genes (26, 27) . The mutant protein inhibits AP-1-mediated processes through a quenching mechanism by inhibiting the function of endogenous fos and/or jun proteins(26) . Lysates of OVCAR-3 cells transfected with the urokinase promoter-CAT reporter, the c-Ha-ras expression vector, and the empty TAM 67 vector (cytomegalovirus vector) resulted in 92% [^14C]chloramphenicol conversion up from 2% in the absence of ras (Fig. 5). In contrast, expression of 1 and 10 µg of the c-jun mutant attenuated the ability of ras to stimulate the urokinase promoter (Fig. 5). Thus, conversion of [^14C]chloramphenicol was reduced to 29% in cells co-transfected with 10 µg of the c-jun mutant. These data suggest that AP-1-binding transcription factors are necessary for the ras-mediated stimulation of the urokinase promoter. The inability of the c-jun mutant to repress the stimulation of the urokinase promoter by ras to the same extent as the urokinase promoter mutated at the AP-1 binding site (at -1967-mutant B) (Fig. 4) may very well reflect an incomplete quenching brought about by expression of the TAM 67 construct.


Figure 5: The stimulation of the urokinase promoter by c-Ha-ras is attenuated by the expression of a transactivation domain-lacking c-jun mutant. OVCAR-3 cells were transiently transfected with 4 µg of a CAT reporter driven by the wild type urokinase promoter and, where indicated, 4 µg of the c-Ha-ras expression vector and the indicated amount of an expression vector encoding a transactivation domain-lacking c-jun protein (TAM 67) or an amount of the empty cytomegalovirus vector equimolar to 10 µg of TAM 67. Transfection efficiencies were determined by assaying for beta-galactosidase activity. After an 8-h incubation with [^14C]chloramphenicol, the cell lysate was extracted with ethyl acetate, and the acetylated products were resolved by thin layer chromatography. The conversion of [^14C]chloramphenicol was determined with a 603 Betascope.



Induction of Urokinase Promoter Activity by ras Is Abolished by the Expression of an ERK1- and ERK2-inactivating Phosphatase (CL100)

It is becoming increasingly apparent that the activity and/or synthesis of a number of transcription factors including fos and c-ets family members is modulated by MAPKs including ERK1 and ERK2(22, 38) . Since our data suggest that transcription factors, which bind to the AP-1 and PEA3 sequences in the urokinase promoter, are important for the induction by ras, we examined the role of these MAPKs in the stimulation of urokinase promoter activity by the oncogene. Toward this end, we used an expression vector which contains the human CL100 cDNA(28) . This encodes a dual specificity (Tyr/Thr) protein phosphatase which inactivates both ERK1 and ERK2(39) . The ability of CL100 to inactivate both ERK1 and ERK2 is of importance to these studies since the simultaneous block of both of these MAPKs is necessary to abrogate the stimulation of AP-1 by phorbol ester and by ras(40) . Expression of the vector encoding the CL100 phosphatase completely abrogated the stimulation of urokinase promoter activity by c-Ha-ras (Fig. 6A) whereas the vector lacking the coding sequence of CL100 (pSG5) had only a minimal effect on this stimulation.


Figure 6: Abrogation of the c-Ha-ras-dependent induction of urokinase promoter activity by an ERK1/ERK2-inactivating phosphatase. OVCAR-3 cells were transiently transfected and assayed for CAT activity as described in the legend to Fig. 2. Cells were transfected with a CAT reporter driven by either the wild type urokinase promoter (7 µg) (A) or 3 AP-1 tandem repeats (3 times AP-1 pBLCAT) upstream of a thymidine kinase minimal promoter (pBLCAT) (1 µg) (B) with (+), or without(-), 3 µg of the c-Ha-ras expression vector (c-Ha-ras) or a vector control (pSV2neo) in the presence of the indicated amount of the CL100-encoding expression vector (CL100 SG5) or the empty vector (pSG5 vector equimolar with 10 µg of CL100 SG5). Cell extract, normalized for differences in transfection efficiency, was incubated with [^14C]chloramphenicol, and the reaction products were extracted with ethyl acetate and subjected to thin layer chromatography. The conversion of [^14C]chloramphenicol was determined with a 603 Betascope.



Since AP-1-binding transcription factors are required for the stimulation of the urokinase promoter by ras, we determined whether the expression of CL100 could also repress the induction of an AP-1-driven promoter by ras. OVCAR-3 cells were transiently transfected with a CAT reporter driven by 3 AP-1 tandem repeats (3 times AP-1 pBLCAT) upstream of a thymidine kinase minimal promoter (pBLCAT) and the ras expression vector with, or without, the CL100-encoding expression vector. Expression of ras caused a marked stimulation of the AP-1-driven CAT reporter (Fig. 6B) in OVCAR-3 cells, whereas the activity of the thymidine kinase minimal promoter-CAT reporter (pBLCAT), which was negligible, was unaffected by the oncogene. Co-expression of the CL100-encoding vector (CL100 SG5) countered the ras-dependent induction of the AP-1-driven CAT reporter. The highest level of the CL100-encoding vector (10 µg), but not the empty vector (pSG5), completely abolished the stimulation of the AP-1-driven CAT reporter by ras. Although the CL100-encoding vector also repressed the basal activity of the 3 times AP-1 pBLCAT vector, the amount of this repression was insufficient to account for the MAPK phosphatase-mediated suppression of the ras response. These data indicate that the induction of AP-1 activity by ras, which is critical for the stimulation of the urokinase promoter by the oncogene, is effectively countered by co-expression of a MAPK-inactivating phosphatase.

Expression of a Catalytically Inactive MAPKK (MEK1) Inhibits the Stimulation of the Urokinase Promoter by ras

The ability of a MAPK-inactivating phosphatase (CL100) to counter the stimulation of the urokinase promoter by ras was consistent with the notion of ERK involvement. However, since there are conflicting reports concerning the specificity of this MAPK-inactivating phosphatase toward the ERK-subgroup of MAPKs(41, 42) , we asked whether the expression of a functionally inactive upstream activator of ERKs (29) would abrogate the stimulation of the urokinase promoter by ras. MEK1 is a specific activator of the ERKs(21, 43) , and we made use of a mutant MEK1 expression vector (MEK K97M) in which a methionine is substituted for a lysine at the ATP binding site of the enzyme rendering it catalytically inactive(29, 30) . We transiently transfected (Fig. 7) OVCAR-3 cells with the urokinase promoter-driven CAT reporter and ras in the presence of an expression vector encoding the MEK K97M mutant. The stimulation of the urokinase promoter by the oncogene ([^14C]chloramphenicol acetylation increased from 4 to 17%) was almost entirely abrogated by co-expression of the catalytically inactive MAPKK (6% [^14C]chloramphenicol conversion was evident with 10 µg of the MEK K97M). In contrast, expression of the wild type MAPKK (MEK wt) had little effect on either the basal or the ras-dependent activation of the urokinase promoter activity. The inability of the wild type MAPKK to stimulate the basal activity of the urokinase-driven CAT reporter (i.e. in the absence of ras) in the OVCAR-3 cells is consistent with a report by Mansour et al.(29) showing that this expression vector does not activate an AP-1-driven CAT reporter nor does it transform NIH 3T3 cells. These data indicate that a MAPKK, which functions as an ERK activator, is necessary (but possibly by itself insufficient) for the regulation of urokinase promoter activity by ras.


Figure 7: Expression of a catalytically inactive MAPKK attenuates the ability of ras to stimulate the urokinase promoter. OVCAR-3 cells were transiently transfected and assayed for CAT activity as described in the legend to Fig. 2. Cells were co-transfected with 7 µg of a CAT reporter driven by the wild type urokinase promoter (u-PA) with (+) or without(-) 4 µg of the c-Ha-ras expression vector (c-Ha-ras) in the presence of the indicated amount of an expression vector encoding either the wild type (MEK wt) or point-mutated (MEK K97M) MEK1 sequence(29) . Cell extract, normalized for differences in transfection efficiency, was incubated with [^14C]chloramphenicol, and the reaction products were extracted with ethyl acetate and subjected to thin layer chromatography. The amount of acetylated [^14C]chloramphenicol was determined on a 603 Betascope.



Co-expression of a Dominant Negative c-raf Expression Vector Abrogates the Stimulation of the Urokinase Promoter by ras

Since c-raf is an upstream activator of MAPKK(19, 20, 44) , we then determined the sensitivity of urokinase expression to a dominant negative c-raf expression vector. OVCAR-3 cells were transiently transfected with the urokinase promoter-driven CAT reporter and the ras expression vector in the presence of increasing amounts of a dominant negative c-raf expression vector (raf C4). This vector encodes the amino-terminal 257 amino acids of c-raf(18) and is therefore kinase-deficient. Expression of the raf C4 led to a dose-dependent reduction in the ability of the ras expression vector to stimulate the urokinase promoter (Fig. 8). Thus, while a conversion of [^14C]chloramphenicol of 43% was apparent in OVCAR-3 cells transiently transfected with ras and the urokinase promoter-CAT reporter, this was reduced to 7% in the presence of 0.1 µg of the dominant negative raf C4 expression vector. In contrast, the empty vector lacking the c-raf coding sequence failed to repress the induction of the CAT reporter by ras. Although the raf C4 expression vector also reduced the basal activity of the urokinase promoter (i.e. in the absence of ras), the magnitude of this response could not account for the reduction observed in the presence of the activated oncogene. These data are consistent with the hypothesis that the activation of the urokinase promoter by ras in the OVCAR-3 cells is dependent on c-raf. However, since the mutant protein encoded by the raf C4 expression vector binds to the effector domain of ras(45) , we cannot completely rule out the possibility that the raf C4 dominant negative vector is functioning in the OVCAR-3 cells by interfering in the activation of ras effectors other than c-raf.


Figure 8: Abrogation of the c-Ha-ras-dependent induction of urokinase promoter activity by expression of a dominant negative c-raf. OVCAR-3 cells were transiently transfected and assayed for CAT activity as described in the legend to Fig. 2. Briefly, cells were transfected with 7 µg of a CAT reporter driven by the wild type urokinase promoter with (+) or without(-) 4 µg of the c-Ha-ras expression vector (c-Ha-ras) in the presence of the indicated amount of an expression vector encoding a kinase domain-lacking c-raf (raf C4) or an amount of the empty expression vector (Vector) equimolar with 4 µg of the raf C4. Cell extract, normalized for differences in transfection efficiency, was incubated with [^14C]chloramphenicol, and the reaction products were extracted with ethyl acetate and subjected to thin layer chromatography. The amount of acetylated [^14C]chloramphenicol was determined on a 603 Betascope.




DISCUSSION

Urokinase gene expression is regulated by a diverse set of growth factors which interact with transmembrane receptor tyrosine kinases including HGF/SF and EGF as well as by non-membrane tyrosine kinases including v-src(11, 12, 13) . Although there is ample evidence that these tyrosine kinases mediate their effects via ras-dependent pathways(16) , the downstream event(s) by which ras stimulates urokinase gene expression has not been determined, and it now appears that ras can stimulate at least 2 distinct pathways, one which is c-raf-dependent, the other c-raf-independent(24) . Stimulation of the c-raf-dependent pathway by ras leads to the sequential activation of MAPKK and the ERK group of the MAPKs (19, 20, 21) . The ERKs phosphorylate several transcription factors including p62/elk, this leading to increased AP-1 activity as a consequence of enhanced fos gene transcription (22) . Several observations in this, and other, studies suggest that the induction of urokinase promoter activity by ras occurs through this pathway. Firstly, expression of the ERK1/ERK2-inactivating CL100 phosphatase efficiently blocked the ras signal in OVCAR-3 cells. Secondly, an expression construct encoding a catalytically inactive MEK1, which is specific for the ERKs, substantially reduced the ability of ras to stimulate the urokinase promoter. Thirdly, the block of c-raf, which is an upstream effector of MEK1(19, 44) , with a dominant negative expression vector, completely abrogated the ras-dependent stimulation of the urokinase promoter. Thus, together these data would suggest a pivotal role for one, or multiple, ERKs in the stimulation of the urokinase promoter by ras and are consistent with the hypothesis that this is achieved by the c-raf-dependent pathway described by Minden et al.(24) . Additionally, since dominant negative mutants to ERK1 and ERK2 also block AP-1 activation (an event necessary for the induction of the urokinase promoter by ras) as well as the proliferation response to growth factors including EGF(40, 46) , it may very well be that the ability of these stimuli to elevate urokinase expression (47) is mediated through this pathway.

Further evidence that the regulation of urokinase expression by ras is mediated through a c-raf-dependent pathway comes from studies with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. TPA, via protein kinase C, is an activator of c-raf(48) , and treatment of cells with this agent leads to a strong activation of urokinase gene transcription(49) . The transcriptional requirements for urokinase promoter stimulation by TPA (32) and ras are similar in that mutation of the PEA3 and AP-1 motifs (-1973 and -1967, respectively), as well as a region shown to be required for the efficient induction of urokinase gene expression by the phorbol ester (32) , substantially impaired the ability of the oncogene as well as TPA to stimulate the promoter. Presumably, these findings for ras reflect the well characterized observations of increased AP-1 and PEA3 activity brought about by the oncogene as a consequence of increased synthesis, or activation by phosphorylation, of c-jun, c-fos, and c-ets family members (50, 51) .

While these data suggest the involvement of ERKs in the regulation of urokinase expression by ras, we cannot currently exclude a role for the JNKs in this process. ras, via MEKK, is an inducer of JNK(24) , and this leads to increased AP-1 activity subsequent to c-jun phosphorylation(23) . However, any speculation as to the role of JNKs in the regulation of urokinase expression by ras must take into account our observations that interfering with the ERK pathway with a MEK1 mutant, or with a dominant negative c-raf expression vector, effectively suppresses the ras stimulus. Thus, either the JNKs play only a minor role in the regulation of urokinase expression by the oncogene or alternatively both ERKs and JNKs are concurrently required for the stimulation of urokinase promoter activity by ras. Notwithstanding these considerations, our findings favor a key role for the ERKs in the stimulation of urokinase promoter by ras.

In conclusion, we have shown that the induction of urokinase promoter activity by an activated c-Ha-ras requires a PEA3/AP-1 sequence in the urokinase promoter and is mediated through a c-raf and MAPK-dependent signal transduction pathway. Since several tyrosine kinases including the receptors for EGF (c-erbB1), and HGF/SF (p190), as well as the non-receptor tyrosine kinase v-src, mediate their effects through ras, it is interesting to speculate that c-raf and/or the MAPKs may represent novel therapeutic targets for repressing the elevated synthesis of the plasminogen activator in invasive cancer which is driven by both autocrine and paracrine mechanisms.


FOOTNOTES

*
This work was supported by National Institutes of Health Grants R01DE10845 and R01CA58311 and Council for Tobacco Research Grant 3438 (to D. B.) and a fellowship from the Deutsche Forschungsgemeinschaft, German Research Council Grant Le 889/1-1 (to E. L.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Dept of Tumor Biology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030. Tel.: 713-792-8953; Fax: 713-794-0209; douglasdw{at}odin.mda.uth.tmc.edu.

(^1)
The abbreviations used are: HGF/SF, hepatocyte growth factor/scatter factor; EGF, epidermal growth factor; MAPK, mitogen-activated protein kinase; MAPKK (MEK), mitogen-activated protein kinase kinase; CAT, chloramphenicol acetyltransferase; bp, base pair(s); TPA, 12-O-tetradecanoylphorbol-13-acetate.

(^2)
G. Mills, personal communication.


ACKNOWLEDGEMENTS

We are grateful to Drs. Claus Nerlov (University of Copenhagen, Denmark) and Francesco Blasi (University of Milan, Italy) for the urokinase promoter-CAT constructs. We are indebted to Dr. Michael Birrer (Biomarkers and Prevention Research Branch, National Institutes of Health, Bethesda) for supplying the TAM 67 expression construct, to Dr. Stephen Keyse for the CL100 expression vector (I.C.R.F., Dundee, Scotland), and to Dr. Ulf Rapp (Institute of Radiobiology, University of Wurzburg, Germany) for the c-raf C4 expression vector. Natalie Ahn (University of Colorado, Boulder) kindly provided the MEK expression vectors. American Diagnostica generously supplied the anti-urokinase antibody for Western blotting. We thank Dr. Michael Tainsky (M.D. Anderson Cancer Center, Houston) for the c-Ha-ras expression vector and for his critical appraisal of the manuscript. We thank Dr. Manfred Schmitt (Technical University of Munich, Germany) for the OVCAR-3 cells.


REFERENCES

  1. Strickland, S., Reich, E., and Sherman, M. I. (1976) Cell 9,231-240 [Medline] [Order article via Infotrieve]
  2. Andreasen, P., Kristensen, P., Lund, L. R., and Dano, K. (1990) Endocrinology 126,2567-2576 [Abstract]
  3. Tryggvason, K., Hoyhtya, M., and Salo, T. (1987) Biochim. Biophys. Acta 907,191-217 [CrossRef][Medline] [Order article via Infotrieve]
  4. Liotta, L., Goldfarb, R., Brundage, R., Siegel, G., Terranova, V., and Garbisa, S. (1981) Cancer Res. 41,4629-4636 [Abstract]
  5. Salo, T., Liotta, L., Keski-Oja, J., Turpeenniemi-Hujanen, T., and Tryggvason, K. (1982) Int. J. Cancer 30,669-673 [Medline] [Order article via Infotrieve]
  6. Verde, P., Stoppelli, M. P., Galeffi, P., Di Nocera, P., and Blasi, F. (1984) Proc. Natl. Acad. Sci. U. S. A. 81,4727-4731 [Abstract]
  7. Kasai, S., Arimura, H., Nishida, M., and Suyama, T. (1985) J. Biol. Chem. 260,12382-12389 [Abstract/Free Full Text]
  8. Nielsen, L., Hansen, J., Skriver, L., Wilson, E., Kaltoft, K., Zeuthen, J., and Dano, K. (1982) Biochemistry 21,6410-6415 [Medline] [Order article via Infotrieve]
  9. Verde, P., Boast, S., Franze, A., Robbiati, F., and Blasi, F. (1988) Nucleic Acids Res. 16,10699-10715 [Abstract]
  10. Nanbu, R., Menoud, P., and Nagamine, Y. (1995) Mol. Cell. Biol. 14,4920-4928 [Abstract]
  11. Pepper, M. S., Matsumoto, K., Nakamura, T., Orei, L., and Montesano, R. (1992) J. Biol. Chem. 267,20493-20496 [Abstract/Free Full Text]
  12. Grimaldi, G., Di Fiore, P., Locatelli, E. K., Falco, J., and Blasi, F. (1986) EMBO J. 5,855-861 [Abstract]
  13. Bell, S. M., Connoly, D. C., Maihle, N. J., and Degen, J. L. (1993) Mol. Cell. Biol. 13,5888-5897 [Abstract]
  14. Graziani, A., Gramaglia, D., dalla Zonca, P., and Comoglio, P. M. (1993) J. Biol. Chem. 268,9165-9168 [Abstract/Free Full Text]
  15. Sasaoka, T., Langlois, W. J., Leitner, J. W., Draznin, B., and Olefsky, J. M. (1994) J. Biol. Chem. 268,32621-32625
  16. Stacey, D. W., Roudebush, M., Day, R., Mosser, S. D., Gibbs, J. B., and Feig, L. A. (1991) Oncogene 6,2297-2304 [Medline] [Order article via Infotrieve]
  17. Kuzumaki, N., Ggiso, Y., Oda, A., Fujita, H., Suzuki, H., Sato, C., and Mullauer, L. (1989) Mol. Cell. Biol. 9,2258-2263 [Medline] [Order article via Infotrieve]
  18. Bruder, J. T., Heidecker, G., and Rapp, U. R. (1992) Genes & Dev. 6,545-556
  19. Kyriakis, J. M., App, H., Zhang, X., Banerjee, P., Brautigan, D. L., Rapp, U. R., and Avruch, J. (1992) Nature 358,417-420 [CrossRef][Medline] [Order article via Infotrieve]
  20. Huang, W., Alessandrini, A., Crews, C. M., and Erikson, R. L. (1993) Proc. Natl. Acad. Sci. U. S. A. 90,10947-10951 [Abstract]
  21. Crews, C. M., Alessandrini, A., and Erikson, R. L. (1992) Science 258,478-480 [Medline] [Order article via Infotrieve]
  22. Gille, H., Sharrocks, A. D., and Shaw, P. E. (1992) Nature 358,414-417 [CrossRef][Medline] [Order article via Infotrieve]
  23. Hibi, M., Lin, A., Minden, A., and Karin, M. (1993) Genes & Dev. 7,2135-2148
  24. Minden, A., Lin, A., McMahon, M., Lange-Carter, C., Derijard, B., Davis, R. J., Johnson, G. L., and Karin, M. (1994) Science 266,1719-1722 [Medline] [Order article via Infotrieve]
  25. Nicolson, G. L., Gallick, G. E., Dulski, K., Spohn, W. H., Lembo, T. M., and Tainsky, M. A. (1990) Oncogene 5,747-753 [Medline] [Order article via Infotrieve]
  26. Brown, P. H., Alani, R., Preis, L. H., Szabo, E., and Birrer, M. J. (1993) Oncogene 8,877-886 [Medline] [Order article via Infotrieve]
  27. Domann, F. E., Levy, J. P., Birrer, M. J., and Bowden, G. T. (1994) Cell Growth Differ. 5,9-16 [Abstract]
  28. Keyse, S. M., and Emslie, E. A. (1992) Nature 359,644-647 [CrossRef][Medline] [Order article via Infotrieve]
  29. Mansour, S. J., Matten, W. T., Hermann, A. S., Candia, J. M., Rong, S., Fukusawa, K., Vande Woude, G. F., and Ahn, N. G. (1994) Science 265,966-970 [Medline] [Order article via Infotrieve]
  30. Al-Alawi, N., Rose, D. W., Buckmaster, C., Ahn, N., Rapp, U., Meinkoth, J., and Feramisco, J. R. (1995) Mol. Cell. Biol. 15,1162-1168 [Abstract]
  31. Angel, P., Hattori, K., Smeal, T., and Karin, M. (1988) Cell 55,875-885 [Medline] [Order article via Infotrieve]
  32. Nerlov, C., De Cesare, D., Pergola, F., Caracciolo, A., Blasi, F., Johnsen, M., and Verde, P. (1992) EMBO J. 11,4573-4582 [Abstract]
  33. Hamilton, T. C., Young, R. C., McKoy, W. M., Grotzinger, K. R., Green, J. A., Chu, E. W., Whang-Peng, J., Rogan, A. M., Green, W. R., and Ozols, R. F. (1983) Cancer Res. 43,5379-5389 [Abstract]
  34. Pankov, R., Umezawa, A., Maki, R., Der, C., Hauser, C. A., and Oshima, R. G. (1994) Proc. Natl. Acad. Sci. U. S. A. 91,873-877 [Abstract]
  35. Nerlov, C., Rorth, P., Blasi, F., and Johnsen, M. (1991) Oncogene 6,1583-1593 [Medline] [Order article via Infotrieve]
  36. Galang, C. K., Der, C. J., and Hauser, C. A. (1994) Oncogene 9,2913-2921 [Medline] [Order article via Infotrieve]
  37. Wasylyk, C., Maira, S. M., Sobieszczuk, P., and Wasylyk, B. (1994) Oncogene 9,3665-3673 [Medline] [Order article via Infotrieve]
  38. O'Neill, E. M., Rebay, I., Tjian, R., and Rubin, G. M. (1994) Cell 78,137-147 [Medline] [Order article via Infotrieve]
  39. Alessi, D. R., Smythe, C., and Keyse, S. M. (1993) Oncogene 8,2015-2020 [Medline] [Order article via Infotrieve]
  40. Frost, J. A., Geppert, T. D., Cobb, M. H., and Feramisco, J. R. (1994) Proc. Natl. Acad. Sci U. S. A. 91,3844-3848 [Abstract]
  41. Sun, H., Tonks, N., and Bar-Sagi, D. (1994) Science 266,285-288 [Medline] [Order article via Infotrieve]
  42. Liu, Y., Gorospe, M., Yang, C., and Holbrook, N. J. (1995) J. Biol. Chem. 270,8377-8380 [Abstract/Free Full Text]
  43. Derijard, B., Raingeaud, J., Barrett, T., Wu, I., Han, J., Ulevitch, J., and Davis, R. J. (1995) Science 267,682-685 [Medline] [Order article via Infotrieve]
  44. Jelinek, T., Catling, A. D., Reuter, C. W. M., Moodie, S. A., Wolfman, A., and Weber, M. J. (1994) Mol. Cell. Biol. 14,8212-8218 [Abstract]
  45. Warne, P. H., Rodriguez Viciana, P., and Downward, J. (1993) Nature 364,352-355 [CrossRef][Medline] [Order article via Infotrieve]
  46. Sontag, E., Fedorov, S., Kamibayashi, C., Robbins, D., Cobb, M., and Mumby, M. (1993) Cell 75,887-897 [Medline] [Order article via Infotrieve]
  47. Rorth, P., Nerlov, C., Blasi, F., and Johnsen, M. (1990) Nucleic Acids Res. 18,5009-5017 [Abstract]
  48. Sozeri, O., Vollmer, K., Liyanage, M., Frith, D., Kour, G., Mark, G. E., and Stabel, S. (1992) Oncogene 7,2259-2262 [Medline] [Order article via Infotrieve]
  49. Stoppelli, P., Verde, P., Grimaldi, G., Locatelli, E., and Blasi, F. (1986) J. Cell Biol. 102,1235-1241 [Abstract]
  50. Imler, J. L., Schatz, C., Wasylyk, C., Chatton, B., and Wasylyk, B. (1988) Nature 332,275-278 [Medline] [Order article via Infotrieve]
  51. Sistonen, L., Holtta, E., Makela, T. P., Keski-Oja, J., and Alitalo, K. (1989) EMBO J. 8,815-822 [Abstract]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.